Sugi Predict

Sugi Predict / Compounds / SCHEMBL4038901

SCHEMBL4038901

SCHEMBL4038901

CCOC(=O)C1CN(C(=O)OC(C)(C)C)CCN1C(=O)c1ccncc1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SETD7 Q8WTS6 2/20 0.45
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ GPR119 Q8TDV5 5/20 0.42
▸ GAA P10253 2/20 0.42
▸ ATM Q13315 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ USP30 Q70CQ3 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6194002 0.94 GPR119 (0.50) SETD7MEN1KMT2AGPR119ATM
SCHEMBL4040548 0.89 SETD7 (0.46) SETD7MEN1KMT2AGPR119KDM4E
SCHEMBL4038706 0.86 GPR119 (0.46) MEN1KMT2ASMN1; SMN2GPR119GAA
SCHEMBL6199875 0.86 GPR119 (0.54) SETD7GPR119GAAUSP30
SCHEMBL2865263 0.83 MEN1 (0.43) SETD7MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL14251810 0.83 MEN1 (0.43) SETD7MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL4038489 0.82 POLB (0.50) MEN1KMT2AGPR119ATM
SCHEMBL4043624 0.81 MEN1 (0.40) SETD7MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL4041583 0.78 HPGD (0.44) MEN1KMT2AKDM4EGLATSHR
SCHEMBL3960220 0.77 MEN1 (0.66) MEN1KMT2ASMN1; SMN2GPR119GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079728-A1 N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES Amgen Inc. (US) 2009-07-22 — — EP disclosed
EP-1436291-B1 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA SA (FR) 2009-01-14 — — EP disclosed
WO-2008045484-A1 N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES AMGEN INC. (US) 2008-04-17 — — WO disclosed
US-20070238734-A1 JNK INHIBITORS SANOLI-AVENTIS (FR) 2007-10-11 — — US disclosed
US-7148215-B2 Prodrugs as antihistamines or anticarcinogenic agents AVENTIS PHARMA S.A. (FR) 2006-12-12 — — US disclosed
US-20050009831-A1 Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents AVENTIS PHARMA S.A, (FR) 2005-01-13 — — US disclosed
EP-1436291-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS Aventis Pharma S.A. (FR) 2004-07-14 — — EP disclosed
WO-2003024967-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA S.A. (FR) 2003-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238734-A1 JNK INHIBITORS MAP3K7, MAPKAPK2, MAPK7 SETD7 2653/4885MEN1 3865/4885KMT2A 2686/4885
US-20050009831-A1 Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents CNKSR1, ROS1, NRAS SETD7 2544/4885MEN1 3716/4885KMT2A 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.